0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD40

CD40

CD40 Molecule Information

Name:Tumor necrosis factor receptor superfamily member 5
Target Synonym:B Cell-Associated Molecule,CD40 Antigens,Bp50,CD40 Molecule,Tumor Necrosis Factor Receptor Superfamily, Member 5,B Cell Surface Antigen CD40,B-Cell Surface Antigen CD40,CD40L Receptor,CD40,CDW40,Tumor Necrosis Factor Receptor Superfamily Member 5,TNFRSF5,
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:17
Lastest Research Phase:Phase 2 Clinical

CD40 Protein Product ListCompare or Buy

CD40 Part of Bioactivity data

CD0-H525a-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that Human CD40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD0-H525a) can bind to 293T cells overexpressing human CD40L. The concentration of Human CD40 is 0.03 μg/ml (Routinely tested).

TN5-H82F9-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that Biotinylated Human CD40, Fc,Avitag (Cat. No. TN5-H82F9) can bind to 293T cells overexpressing human CD40L. The concentration of Biotinylated Human CD40 is 0.1 μg/mL (Routinely tested).

CD0-H525a-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Human CD40, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. CD0-H525a) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.911 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD0-C5259-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Rhesus macaque CD40, Fc Tag (Cat. No. CD0-C5259) on Protein A Biosensor, can bind Human CD40 Ligand, His,Flag Tag (active trimer) (MALS verified) (Cat. No. CDL-H52Db) with an affinity constant of 0.829 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD40 Customer Reviews

CD40 Molecule Synonym Name

CD40,Bp50,CDW40,MGC9013,TNFRSF5,p50

CD40 Molecule Background

CD40 is also known as TNFRSF5, Bp50, CDW40, MGC9013, TNFRSF5 and  p50, is a member of the TNF receptor superfamily which are single transmembrane-spanning glycoproteins, and plays an essential role in mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. CD40 is a costimulatory protein found on antigen presenting cells and is required for their activation. The binding of CD154 (CD40L) on TH cells to CD40 activates antigen presenting cells and induces a variety of downstream effects. CD40 contains 4 cysteine-rich repeats in the extracellular domain, and is expressed in B cells, dendritic cells, macrophages, endothelial cells, and several tumor cell lines. The extracellular domain has the cysteinerich repeat regions, which are characteristic for many of the receptors of the TNF superfamily. Interaction of CD40 with its ligand, CD40L, leads to aggregation of CD40 molecules,which in turn interact with cytoplasmic components to initiate signaling pathways. Early studies on the CD40-CD40L system revealed its role in humoral immunity. Defects in CD40 result in hyper-IgM immunodeficiency type 3 (HIGM3), an autosomal recessive disorder characterized by an inability of B cells to undergo isotype switching, as well as an inability to mount an antibody-specific immune response, and a lack of germinal center formation.

CD40 References

CD40 Related Molecule

CD40 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CD40L-GVAX GM.CD40L; CD40L-GVAX; GM-CSF/CD40L; hCD40L/hGM-CSF Phase 2 Clinical University Of South Florida Myelodysplastic Syndromes; Lung Neoplasms; Melanoma Details
FFP-102 5-D12; PG-102 Phase 2 Clinical Pangenetics Arthritis, Psoriatic; Crohn Disease Details
Autologous IL2 and CD40 ligand-expressing tumor cells (Baylor College of Medicine) Phase 1 Clinical Baylor College Of Medicine Leukemia, Lymphocytic, Chronic, B-Cell Details
2141-V11 2141-V11 Darell Bigner Details
BI-655064 BI-655064 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Purpura, Thrombocytopenic, Idiopathic; Arthritis, Rheumatoid; Lupus Nephritis Details
CDX-1140 CDX-1140 Phase 2 Clinical Celldex Lymphoma, Follicular; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Waldenstrom Macroglobulinemia; Colorectal Neoplasms; Peritoneal Neoplasms; Lymphoma, Mantle-Cell; Breast Neoplasms; Cholangiocarcinoma; Lymphoma, B-Cell, Marginal Zone; Urinary Bladder Neoplasms; Lymphoma, Large B-Cell, Diffuse; Pancreatic Neoplasms; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Lymphoma, B-Cell; Head and Neck Neoplasms; Ovarian Neoplasms; Liver Neoplasms Details
NJA-730 NJA-730; NJA-730a; NJA-730b Phase 1 Clinical Napajen Pharma Graft vs Host Disease; Autoimmune Diseases of the Nervous System Details
Mitazalimab ADC-1013; JNJ-7107; JNJ-64457107 Phase 1 Clinical Alligator Bioscience Solid tumours; Neoplasms Details
FFP-104 FFP-104 Phase 2 Clinical Ff Pharma Liver Cirrhosis, Biliary; Crohn Disease Details
Ravagalimab ABBV-323; PR-1629977 Phase 2 Clinical Abbvie Inc Colitis, Ulcerative Details
SHR-1704 SHR-1704 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd Hematologic Diseases Details
MEDI-5083 MEDI-5083 Phase 1 Clinical Astrazeneca Plc, Medimmune Neoplasms Details
APX-005M APX-005; APX-005M; EPI-0050 Phase 2 Clinical Epitomics Head and Neck Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Sarcoma; Brain Neoplasms; Microsatellite Instability; Glioma; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Bleselumab 4D-11; ASKP-1240 Phase 2 Clinical Kyowa Hakko Kogyo Rejection of organ transplantation; Glomerulosclerosis, Focal Segmental; Psoriasis Details
Anti-CD40 ChiLob7/4 (BioNTech) Phase 2 Clinical Biontech Se Head and Neck Neoplasms; Pancreatic Neoplasms Details
Iscalimab CFZ-533; NVP-CFZ533; OM11-62-MF Phase 2 Clinical Novartis Pharma Ag Myasthenia Gravis; Rejection of renal transplantation; Diabetes Mellitus, Type 1; Rejection of liver transplantation; Arthritis, Rheumatoid; Sjogren's Syndrome; Lupus Nephritis; Lupus Erythematosus, Systemic; Graves Disease; Sjogren-Larsson Syndrome; Hidradenitis Suppurativa Details
SEA-CD40 SEA-CD40 Phase 1 Clinical Seattle Genetics Lymphoma, B-Cell; Head and Neck Neoplasms; Squamous Cell Carcinoma of Head and Neck; Hodgkin Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms, Squamous Cell; Pancreatic Neoplasms; Lymphoma, Follicular; Lymphoma; Lymphoma, Non-Hodgkin; Carcinoma, Squamous Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis Details
Selicrelumab RG-7876; RO-7009789 Phase 1 Clinical F. Hoffmann-La Roche Ltd Solid tumours; Pancreatic Neoplasms; Neoplasms; Lymphoma, Non-Hodgkin Details
YH-003 YH-003; YH003 Phase 1 Clinical Eucure Pharmaceutical Technology (Beijing) Co Ltd Neoplasms Details

This web search service is supported by Google Inc.

totop